Research on the Therapeutic Effects and Safety of Compound Shenjin Capsules with Febuxostat in Gout-Related Hyperuricemia

目的：观察非布司他联合复方伸筋胶囊对痛风伴高尿酸血症的影响。方法：将60例痛风伴高尿酸血症患者分为对照组(非布司他治疗组)和观察组(常规非布司他治疗联合复方伸筋胶囊组)，每组30例。治疗持续4周，观察两组患者治疗前后血尿酸(UA)、C反应蛋白及黄嘌呤氧化酶(XOD)水平的变化，同时监测肝肾功能及不良反应。结果：治疗4周后，观察组较对照组更显著降低血尿酸水平((370 ± 27.5) μmol/L vs. (412 ± 22.5) μmol/L, P Objective: To observe the effects of febuxostat combined with Compound Shenjin Capsules on gout with hyperuricemia. Methods: Sixty patients with gout and hyperuricemia were divided into a control group (febuxostat treatment group) and an observation group (febuxostat combined with Compound Shenjin Capsules), with 30 patients in each group. The treatment lasted for 4 weeks. Changes in serum uric acid (UA), C-reactive protein (CRP), and xanthine oxidase (XOD) levels were observed before and after treatment in both groups. Liver and kidney function, as well as adverse reactions, were also monitored. Results: After 4 weeks of treatment, the observation group showed a significantly greater reduction in serum uric acid levels ((370 ± 27.5) μmol/L vs. (412 ± 22.5) μmol/L, P < 0.05), CRP levels ((10.1 ± 1.8) mg/L vs. (13.2 ± 2.0) mg/L, P < 0.05), and XOD activity (9.1 ± 2.1 vs. 17.2 ± 1.9, P = 0.001) compared to the control group. No serious adverse reactions were observed. Conclusion: Febuxostat combined with Compound Shenjin Capsules effectively reduces serum uric acid levels and inflammation in gout patients and demonstrates good safety in terms of liver and kidney function.